Siel Olbrecht

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: Research square

Published: November 19, 2025

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: October 03, 2025

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: Nature communications

Published: September 22, 2025

Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.

Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.

Journal: British journal of cancer

Published: November 13, 2024

Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment.

Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment.

Journal: Cell reports. Medicine

Published: September 27, 2024

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2023

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

Journal: Cancer

Published: June 17, 2022

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Journal: European journal of human genetics : EJHG

Published: March 22, 2022

Systematic study of tissue factor expression in solid tumors.

Systematic study of tissue factor expression in solid tumors.

Journal: Cancer reports (Hoboken, N.J.)

Published: January 07, 2022

Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.

Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.

Journal: Gynecologic oncology

Published: November 05, 2021

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Journal: Virchows Archiv : an international journal of pathology

Published: September 13, 2021

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer.

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer.

Journal: NPJ genomic medicine

Published: March 10, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026